Californian biotechnology company Amyris has sold its flavours and fragrance business to Royal DSM, a global science-based company in the nutrition space.
The group has acquired the personal care chemicals giant’s bio-based intermediates business for a US$150m price tag.
As part of the deal, DSM will obtain Amryis’ seven intermediate products to add to its Personal Care & Aroma Ingredients portfolio.
The move follows DSM’s acquisition of Amryis’ Farnesene business, as well as its Brotas biotechnology manufacturing facilities.
“We are pleased that we can extend the offering to our customers with an additional seven important intermediates that will help our flavour and fragrance and cosmetics customers to improve their sustainability profile,” said Gareth Barker, President of DSM Personal Care & Aroma Ingredients.
“These bio-based ingredients provide them with attractive and sustainable additional alternatives,” he added.
